Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
On July 6, 2012, the Administrators of the Deferred Investment Award Programme notified the Company and specific individuals of an increase in their notional interests in Ordinary Shares. This increase resulted from the re-investment of the dividend paid to shareholders on July 5, 2012, at a price of 1,479.75 pence per Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Re-investment of dividends into notional Ordinary Shares under the Deferred Investment Award Programme.
- Share Price: 1,479.75 pence per Share.
- Key Dates: Dividend paid on July 5, 2012; Notification issued on July 6, 2012.
- Participants: Includes Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, Mr C Weber, and Mrs V A Whyte.
- Financial Data: No financial performance metrics are included in this specific filing.